Opus Genetics Inc. (OCUP)
NASDAQ
Closed
Sep 10, 2026
Day's Range
5.4252 wk Range
1.32Overview - OCUP - Opus Genetics Inc.
Key Statistics
Valuation
P/E (Trailing)
‪1.38‬
P/E (Forward)
‪-1.30‬
Price / Sales (TTM)
‪5.46‬
Price / Book
‪3.31‬
Profitability
Operating Margin
‪-52.35%‬
Return on Assets
‪-18.51%‬
Return on Equity
‪-20.00%‬
Ownership
Shares Outstanding
25.97M
Market Cap - OCUP - Opus Genetics Inc.
Peers - OCUP - Opus Genetics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- OCUPNASDAQOpus Genetics Inc.104.18MMarket Cap+67.55%52-week change1.38P/E (Trailing)—Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt64.24BMarket Cap+25.70%52-week change40.24P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.35.60BMarket Cap-70.99%52-week change45.79P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE26.05BMarket Cap-8.41%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S17.75BMarket Cap+23.94%52-week change20.58P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.14.63BMarket Cap+27.46%52-week change-19.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.87BMarket Cap+15.26%52-week change179.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - OCUP - Opus Genetics Inc.
About
Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
